Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice

Regulatory Peptides

Volumn 179, Issue 1-3, 2012, Pages 91-100

  Kissow, Hannelouise ^a   Hartmann, Bolette ^a   Holst, Jens Juul ^a   Viby, Niels Erik ^a   Hansen, Lærke Schmidt ^b   Rosenkilde, Mette Marie ^b   Hare, Kristine Juul ^a   Poulsen, Steen Seier ^a  

^a Capital Region   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adenoma; Colon; Dimethylhydrazine; DPP 4; GLP 2; Mice

Indexed keywords

CARCINOGEN; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 DERIVATIVE; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; HORMONE RECEPTOR; LIRAGLUTIDE; SITAGLIPTIN; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN COS7; COLON; COLON ADENOMA; CONTROLLED STUDY; DYSPLASIA; FEMALE; GENETIC TRANSFECTION; INTESTINE CRYPT; INTESTINE VILLUS; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; ORGAN GROWTH; ORGAN WEIGHT; PRIORITY JOURNAL; SMALL INTESTINE; TUMOR PROMOTION;

1,2-DIMETHYLHYDRAZINE; ABERRANT CRYPT FOCI; ADENOMA; ANATOMY, CROSS-SECTIONAL; ANIMALS; CERCOPITHECUS AETHIOPS; COLON; COLONIC NEOPLASMS; COS CELLS; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INTESTINAL MUCOSA; INTESTINE, SMALL; MICE; MICE, INBRED C57BL; ORGAN SIZE; PEPTIDES; PYRAZINES; RECEPTORS, GLUCAGON; TRANSFECTION; TRIAZOLES; VENOMS;

MUS;

EID: 84867026656     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.08.016     Document Type: Article

References (37)

1. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87(4):1409-1439.
2. Ghatei M.A., Goodlad R.A., Taheri S., et al. Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci 2001, 46(6):1255-1263.
3. Hartmann B., Harr M.B., Jeppesen P.B., et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000, 85(8):2884-2888.
4. Eng J., Kleinman W.A., Singh L., et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267(11):7402-7405.
5. Lund A., Knop F.K., Vilsboll T. Emerging GLP-1 receptor agonists. Expert Opin Emerg Drugs 2011, 16(4):607-618.
6. Astrup A., Rossner S., Van G.L., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374(9701):1606-1616.
7. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003, 17(2):161-171.
8. Xu G., Stoffers D.A., Habener J.F., et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48(12):2270-2276.
9. Buteau J., El-Assaad W., Rhodes C.J., et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47(5):806-815.
10. Simonsen L., Pilgaard S., Orskov C., et al. Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. Am J Physiol Gastrointest Liver Physiol 2007, 293(1):G288-G295.
11. Thulesen J., Hartmann B., Hare K.J., et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004, 53(8):1145-1150.
12. Hartmann B., Johnsen A.H., Orskov C., et al. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000, 21(1):73-80.
13. Scharpe S., De Meester I., Vanhoof G., et al. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine. Clin Chem 1988, 34(11):2299-2301.
14. Bird R.P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987, 37(2):147-151.
15. Graham F.L., van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973, 52(2):456-467.
16. Luthman H., Magnusson G. High efficiency polyoma DNA transfection of chloroquine treated cells. Nucleic Acids Res 1983, 11(5):1295-1308.
17. Elbrond B., Jakobsen G., Larsen S., et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25(8):1398-1404.
18. Kothare P.A., Linnebjerg H., Isaka Y., et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 2008, 48(12):1389-1399.
19. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137(7):2968-2978.
20. Campos R.V., Lee Y.C., Drucker D.J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994, 134(5):2156-2164.
21. Wei Y., Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995, 358(3):219-224.
22. Wei Y., Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996, 157(3):355-357.
23. Orskov C., Poulsen S.S. Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 1991, 40(10):1292-1296.
24. Dunphy J.L., Taylor R.G., Fuller P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998, 141(1-2):179-186.
25. Gallagher E.J., Leroith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010, 21(10):610-618.
26. Delmeire D., Flamez D., Hinke S., et al. Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1. Diabetologia 2003, 46(10):1383-1393.
27. Hartmann B., Thulesen J., Kissow H., et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000, 141(11):4013-4020.
28. Iakoubov R., Lauffer L.M., Trivedi S., et al. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 2009, 150(9):4033-4043.
29. Trivedi S., Wiber S.C., El-Zimaity H.M., et al. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol 2012, 302(8):G840-G849.
30. Holst J.J., Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 2004, 53(Suppl. 3):S197-S204.
31. Fukasawa K.M., Fukasawa K., Sahara N., et al. Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands. J Histochem Cytochem 1981, 29(3):337-343.
32. Masur K., Schwartz F., Entschladen F., et al. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept 2006, 137(3):147-155.
33. Thulesen J., Knudsen L.B., Hartmann B., et al. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 2002, 103(1):9-15.
34. Corpet D.E., Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002, 43(1):1-21.
35. Caderni G., Femia A.P., Giannini A., et al. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 2003, 63(10):2388-2392.
36. Femia A.P., Bendinelli B., Giannini A., et al. Mucin-depleted foci have beta-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazine-treated rats. Int J Cancer 2005, 116(1):9-15.
37. Koehler J.A., Kain T., Drucker D.J. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 2011, 152(9):3362-3372.